Veerendra Munugalavadla

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · The Lancet · 2020 · 583 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +8

Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor

Rebecca J. Chan, Melissa B. Leedy, Veerendra Munugalavadla et al. · Blood · 2005 · 153 citations · Full text

Repression of c-Kit and Its Downstream Substrates by GATA-1 Inhibits Cell Proliferation during Erythroid Maturation

Veerendra Munugalavadla, Louis C. Doré, Bai Lin Tan et al. · Molecular and Cellular Biology · 2005 · 105 citations · Full text

Downstream Substrates, Cell Proliferation, Cell Cycle +16

Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL

Raghuveer Singh Mali, Baskar Ramdas, Peilin Ma et al. · Cancer Cell · 2011 · 96 citations · Full text

Signal Transduction, Signaling Pathway, Rho Kinase +8

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Michael J. Overman, Milind Javle, R. Eric Davis et al. · Journal for ImmunoTherapy of Cancer · 2020 · 88 citations · Full text